Literature DB >> 16606819

Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge.

Pierluigi Tricoci1, Matthew T Roe, Jyotsna Mulgund, L Kristin Newby, Sidney C Smith, Charles V Pollack, Dan J Fintel, Christopher P Cannon, Deepak L Bhatt, W Brian Gibler, E Magnus Ohman, Eric D Peterson, Robert A Harrington.   

Abstract

BACKGROUND: Clopidogrel added to aspirin improved outcomes after hospitalization in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) in the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial, regardless of in-hospital treatment approach. The American College of Cardiology/American Heart Association (ACC/AHA) Guidelines for treating NSTE ACS thus recommend prescribing clopidogrel plus aspirin at discharge for all patients, not just for those undergoing percutaneous coronary intervention (PCI).
METHODS: We studied 61 052 patients with high-risk NSTE ACS (defined as the presence of positive cardiac markers and/or ischemic ST-segment changes) from January 2002 through December 2003 at 461 US hospitals participating in the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) Quality Improvement Initiative. We evaluated temporal trends of clopidogrel use at discharge since the ACC/AHA 2002 Guidelines update and examined variables associated with clopidogrel use in patients who did not undergo PCI.
RESULTS: A total of 34 319 patients (56.2%) received clopidogrel when they were discharged from the hospital. Among patients who did not undergo PCI, variables associated with receiving clopidogrel at discharge included prior PCI, coronary artery bypass grafting (CABG), stroke, or myocardial infarction; hypercholesterolemia; elevated cardiac markers; and cardiology inpatient care. By late 2003, 96.3% of patients who underwent PCI received clopidogrel at discharge, compared with 42.8% of patients who did not undergo cardiac catheterization and 23.5% of the patients who underwent CABG, although clopidogrel prescription at discharge increased in each of these treatment groups from 2002 to 2003.
CONCLUSION: Since release of the ACC/AHA Guidelines recommendations for treatment of NSTE ACS, prescription of clopidogrel at hospital discharge in patients with NSTE ACS who are treated with medical therapy alone and in those who undergo CABG has increased, but most of these patients still do not receive clopidogrel at discharge.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16606819     DOI: 10.1001/archinte.166.7.806

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  13 in total

1.  Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting.

Authors:  Judson B Williams; Renato D Lopes; Gail E Hafley; T Bruce Ferguson; Michael J Mack; C Michael Gibson; Robert A Harrington; Eric D Peterson; Peter K Smith; Rajendra H Mehta; John H Alexander
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

2.  Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery.

Authors:  Renato D Lopes; Rajendra H Mehta; Gail E Hafley; Judson B Williams; Michael J Mack; Eric D Peterson; Keith B Allen; Robert A Harrington; C Michael Gibson; Robert M Califf; Nicholas T Kouchoukos; T Bruce Ferguson; John H Alexander
Journal:  Circulation       Date:  2012-01-11       Impact factor: 29.690

Review 3.  Clopidogrel: a review of its use in the prevention of thrombosis.

Authors:  Greg L Plosker; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  Impediments to adherence to post myocardial infarction medications.

Authors:  Nihar R Desai; Niteesh K Choudhry
Journal:  Curr Cardiol Rep       Date:  2013-01       Impact factor: 2.931

5.  Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study.

Authors:  Rikke Sørensen; G H Gislason; E L Fosbøl; S Rasmussen; L Køber; J K Madsen; C Torp-Pedersen; S Z Abildstrom
Journal:  Br J Clin Pharmacol       Date:  2008-09-23       Impact factor: 4.335

6.  Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies.

Authors:  Niteesh K Choudhry; Troyen Brennan; Michele Toscano; Claire Spettell; Robert J Glynn; Mark Rubino; Sebastian Schneeweiss; Alan M Brookhart; Joaquim Fernandes; Susan Mathew; Blake Christiansen; Elliott M Antman; Jerry Avorn; William H Shrank
Journal:  Am Heart J       Date:  2008-06-06       Impact factor: 4.749

7.  Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes.

Authors:  Bernardo Lombo; José G Díez
Journal:  Core Evid       Date:  2011-03-17

8.  Perioperative Management of Antiplatelet Therapy in Ophthalmic Surgery.

Authors:  Sana Idrees; Jayanth Sridhar; Ajay E Kuriyan
Journal:  Int Ophthalmol Clin       Date:  2020

Review 9.  Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement.

Authors:  Marc Cohen
Journal:  Cardiovasc Drugs Ther       Date:  2009-12       Impact factor: 3.727

10.  Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.

Authors:  Matthew W Sherwood; Stephen D Wiviott; S Andrew Peng; Matthew T Roe; James Delemos; Eric D Peterson; Tracy Y Wang
Journal:  J Am Heart Assoc       Date:  2014-04-14       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.